NCT05757700View on ClinicalTrials.gov

Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Lymphoma

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 23, 2023

Primary Completion Date

February 23, 2026

Study Completion Date

February 23, 2026

Conditions

B-Cell LymphomaLarge B-cell LymphomaDLBCL, Nos Genetic SubtypesHigh-grade B Cell LymphomaMediastinal Large B-cell Lymphoma

Interventions

BIOLOGICAL

19(T2)28z1xx TRAC T cell

"Participants will be treated with escalating doses of modified T cells.~Dose level -1: 3 x 10\^6 Dose level 1: 10 x 10\^6 Dose level 2: 30 x 10\^6 Dose level 3: 100 x 10\^6"

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York